New Retina Radio
01.09.25
What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography. This episode is supported by Zeiss Professional Education.
View full description +
Supported by Zeiss Professional Education
Subscribe
11.25.25
Global Discussions in GA: Educating Patients and Encouraging Follow-UpAnat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD
Editorially independent content, supported by Astellas.
11.25.25
Global Discussions in GA: Referral Patterns and Fellow-Eye MonitoringAnat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD
Editorially independent content, supported by Astellas.
11.21.25
Endophthalmitis Rates With and Without Antibiotic ProphylaxisSruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD
11.17.25
The Nuts and Bolts of GA Therapy: Wrapping Up the ConversationCharles Wykoff, MD, PhD; Sruthi Arepalli, MD; and Kenneth Fan, MD, MBA
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
11.13.25
AAO '25: GLP-1s and AMD, and Parity in Retina CareAleksandra Rachitskaya, MD; and Julia Haller, MD
Editorially independent content, supported by Genentech.
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
Editorially independent content, supported by Genentech.
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
Editorially independent content, supported by Genentech.
11.03.25
The Nuts and Bolts of GA Therapy: The Discussions ContinueCharles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
Show More